Bishal Gyawali, MD, PhD is a medical oncologist from Nepal who has trained and worked in various countries including Nepal, Japan, U.S and Canada. He is currently working as an Associate Professor in the Department of Oncology and Department of Public Health Sciences, and a scientist in the Division of Cancer Care and Epidemiology all through Queen’s University, Kingston, Canada and an affiliated faculty at the Program on Regulation, Therapeutics and Law in the Department of Medicine at Brigham and Women's Hospital, Boston, USA.
Dr. Gyawali is a member of the WHO Essential Medicines List Cancer Medicines Working Group, and the ESMO-Magnitude of Clinical Benefit Scale Extended Working Group. He is also serving as ASCO’s Health Equity and Outcomes Committee member for 2021-2024 term. He is also currently serving as a research consultant to the Nepal Health Research Council and has previously served as a medical consultant for the not-for-profit Anticancer Fund, Belgium. He is in the editorial and advisory board for multiple medicine and oncology journals including Cell, JCO Global Oncology, JCO Oncology Practice and ecancer, has authored or co-authored more than a hundred peer-reviewed articles and is the recipient of the 2020 ASCO Conquer Cancer Foundation Global Oncology Young Investigator Award in Implementation Science. In 2020, Dr. Gyawali was also awarded the Young Health Researcher Award by the Government of Nepal.
Dr. Gyawali’s areas of academic interest include cancer policy, global oncology, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, and supportive care. He is an advocate of "cancer groundshot", a term he coined to imply that investment should be made on proven high-value interventions in cancer care that are easy to implement globally and are affordable.
Dr. Gyawali tweets at @oncology_bg.